Fluorescence-guided surgery has been developing in clinics for several years. While the use of non-targeted dyes may be useful in certain diseases, specific contrast agents are essential in oncology. As shown in the latest clinical studies, monoclonal antibodies have all the characteristics to play a major role in this field of medical imaging, provided the antigenic target is relevant.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1051/medsci/2019207 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnostic performance of particle agglutination tests against electrochemiluminescence immunoassays for the detection of anti-TP antibodies: Evaluation study.
Sex Transm Infect
January 2025
Department of Public Health, College of Health Sciences, Salale University, Fiche, Ethiopia.
Objectives: Although the burden of syphilis is slightly increasing worldwide, there are a limited number of rapid, simple-to-use, accurate and cost-effective diagnostic tools available. Thus, we aimed to determine the diagnostic performance of the particle agglutination (TPPA) test (hereafter called index test) against an electrochemiluminescence immunoassay (ECLIA) (hereafter called reference test). We selected the available treponemal reference test (ECLIA) to evaluate the index test (TPPA) which is not currently in use in Ethiopia.
View Article and Find Full Text PDFClaudins as diagnostic tools and therapeutic targets-Glimpse of the horizon.
Cancer Treat Rev
January 2025
Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London and Surrey, UK. Electronic address:
Claudins (CLDNs) play a crucial and indispensable role as fundamental components within the structure of tight junctions. Due to the distinct and unique distribution pattern exhibited by CLDNs in both normal and malignant tissues, these proteins have garnered significant attention as pivotal targets for systemic anti-cancer therapy and as noteworthy diagnostic markers. This review provides a comprehensive and detailed elucidation of the fundamental understanding surrounding CLDNs, their intricate expression patterns, the potential role they play in cancer diagnosis and therapeutic potentials; all encapsulated within a succinct summary of the cutting-edge advancements and the information derived from various clinical trials.
View Article and Find Full Text PDFActive targeting of type 1 diabetes therapies to pancreatic beta cells using nanocarriers.
Diabetologia
January 2025
Department of Chemical and Biological Engineering, Colorado School of Mines, Golden, CO, USA.
Type 1 diabetes is an autoimmune disease characterised by the destruction of pancreatic beta cells, resulting in lifelong insulin dependence. Although exogenous insulin can maintain glycaemic control, this approach does not protect residual or replacement pancreatic beta cells from immune-mediated death. Current therapeutics designed to protect functional beta cell mass or promote beta cell proliferation and regeneration can have off-target effects, resulting in higher dose requirements and adverse side effects.
View Article and Find Full Text PDFChallenges and Insights in Absolute Quantification of Recombinant Therapeutic Antibodies by Mass Spectrometry: An Introductory Review.
Antibodies (Basel)
January 2025
Federal Institute of Material Testing and Research (BAM), 12489 Berlin, Germany.
This review describes mass spectrometry (MS)-based approaches for the absolute quantification of therapeutic monoclonal antibodies (mAbs), focusing on technical challenges in sample treatment and calibration. Therapeutic mAbs are crucial for treating cancer and inflammatory, infectious, and autoimmune diseases. We trace their development from hybridoma technology and the first murine mAbs in 1975 to today's chimeric and fully human mAbs.
View Article and Find Full Text PDFIdentify biological Alzheimer's disease using a novel nucleic acid-linked protein immunoassay.
Brain Commun
January 2025
Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Montreal, QC, Canada H4H 1R2.
Blood-based biomarkers have been revolutionizing the detection, diagnosis and screening of Alzheimer's disease. Specifically, phosphorylated-tau variants (p-tau, p-tau and p-tau) are promising biomarkers for identifying Alzheimer's disease pathology. Antibody-based assays such as single molecule arrays immunoassays are powerful tools to investigate pathological changes indicated by blood-based biomarkers and have been studied extensively in the Alzheimer's disease research field.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!